You cannot livestream your way out of a federal court order. Martin Shkreli, famously dubbed the Pharma Bro, is learning this lesson the hard way once again.
Federal regulators and a coalition of seven state attorneys general filed a motion in federal court asking a judge to hold Shkreli in civil contempt. The accusation is direct: he flagrantly violated the 2022 lifetime ban that barred him from participating in the pharmaceutical industry.
If you thought a multi-million dollar fine and a federal prison sentence would keep him quiet, you clearly haven't been watching his online broadcasts.
How the Pharma Bro Defied the Court
The 2022 injunction issued by U.S. District Judge Denise Cote didn't just tell Shkreli to step down from running drug companies. It prohibited him from directly or indirectly participating in any manner in the pharmaceutical industry, including trading pharmaceutical stocks or broadcasting his opinions on the business and management of drug companies.
Judge Cote handed down that strict ban after finding Shkreli orchestrated a cold, calculated scheme to protect a monopoly on Daraprim—the critical anti-parasitic medication used by AIDS and cancer patients—after jacking its price overnight from $17.50 to $750 per tablet. Alongside the ban, a federal court ordered him to disgorge more than $64 million in illegal profits, calling his conduct "egregious, deliberate, repetitive, long-running and ultimately dangerous."
Yet, regulators say Shkreli treated that lifetime restriction like an optional suggestion.
According to the Federal Trade Commission and state attorneys general from New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia, Shkreli has been openly trading pharmaceutical stocks across at least 60 companies. Worse, he has been broadcasting his investment strategies and management opinions live on the internet.
During his streams, he openly boasted to viewers, "I'm showing you how to trade and invest in biotech." He even launched public shorting campaigns against specific drug companies, betting out loud that their clinical trials would fail.
What Regulators Are Demanding Now
The FTC and the coalition of states aren't just issuing a warning letter this time. They want real penalties that will actually sting.
The contempt motion asks the federal court to force Shkreli into compliance through severe sanctions:
- Complete divestment of any pharmaceutical company stocks he currently owns.
- A hefty fine equal to every dollar of profit he pulled from trading those drug stocks, plus prejudgment interest, without any ability to write off offsetting losses.
- Clear, escalating consequences for future rule-breaking, which explicitly include the threat of jail time.
New York Attorney General Letitia James didn't mince words about the situation, noting that a court-ordered lifetime ban isn't a suggestion and that public market manipulation puts investors and patients at risk.
Why This Case Matters for Corporate Accountability
People often wonder why white-collar criminals seem to bounce back so fast. They test boundaries, exploit loopholes, and assume that once the media spotlight fades, nobody is watching.
Shkreli's strategy relied on a familiar playbook: find a grey area, claim a technicality, and keep pushing until a judge cracks down. When he launched a software venture called Druglike after his prison release, he argued it sat entirely outside the scope of his pharma ban. But trading public biotech stocks and running short campaigns against clinical trials crosses every bright line the court drew.
Regulators are sending a loud message to other bad actors in the corporate world. When a federal court issues an antitrust injunction or an industry ban, compliance is mandatory. Ignoring the rules invites swift legal retaliation.
If the judge grants the motion, Shkreli will face a reckoning that goes far beyond financial penalties. He might find out firsthand what happens when a federal court tires of watching a convicted felon mock its authority on camera.
